The Medical Letter on Drugs and Therapeutics
Addendum: Treatment of Atrial Fibrillation
Download PDF:   US English
Med Lett Drugs Ther. 2024 Feb 5;66(1695):24   doi:10.58347/tml.2024.1695f
 Select a term to see related articles  anticoagulants   atrial fibrillation 

The Interruption of Anticoagulation section of our article on Treatment of Atrial Fibrillation cited the recommendations of the American College of Chest Physicians on perioperative management of antithrombotic therapy (JD Douketis et al. Chest 2022; 162:e207). A reader suggested that our general statement on when to discontinue an oral anticoagulant would have benefited from inclusion of the recommendations of the American College of Cardiology/American Heart Association (JA Joglar et al. Circulation 2024; 149:e1). Recommendations for periprocedural management of oral anticoagulant therapy vary with the anticoagulant, the bleeding risk of the patient and the procedure, the patient’s thromboembolic risk (CHA2DS2-VASc score), the presence of a mechanical valve, and for some anticoagulants, the patient’s renal function. These recommendations are provided in detail in both of the above-cited guidelines.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article